Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.51 |
| ▸ | HTR6 | P50406 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7676942 | 0.98 | HTR2C (0.53) | HTR2CHTR6EGFRL3MBTL1KEAP1 | |
| Trifluoroacetic Acid SCHEMBL8330605 | 0.88 | HTR2C (0.45) | HTR2CHTR6EGFR | |
| SCHEMBL28604468 | 0.87 | KDM4E (0.42) | HTR2CEGFRL3MBTL1 | |
| SCHEMBL17383406 | 0.82 | HTR6 (0.47) | HTR6 | |
| SCHEMBL22542135 | 0.81 | HTR6 (0.45) | HTR2CHTR6EGFRHTR1ASLC6A2 | |
| SCHEMBL30123462 | 0.79 | KDM4E (0.41) | L3MBTL1KEAP1 | |
| SCHEMBL14417269 | 0.78 | PTGS1 (0.50) | HTR6EGFRL3MBTL1KEAP1 | |
| SCHEMBL20883959 | 0.77 | FASN (0.38) | HTR2CHTR6EGFRL3MBTL1HTR1A | |
| SCHEMBL24628532 | 0.77 | MCOLN2 (0.45) | HTR2CHTR6L3MBTL1KEAP1 | |
| SCHEMBL23323177 | 0.76 | ADRA2A (0.42) | L3MBTL1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B8 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| CN-1309638-A | N-substituted naphthamides as neurokinin receptor antagonists | ASTRAZENECA AB (SE) | 2001-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | HTR2C 129/4885HTR6 206/4885EGFR 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.